{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:47:52Z","timestamp":1787726872156,"version":"build-2784847793"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100015699","name":"Fresenius Medical Care","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015699","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Universit\u00e0 Commerciale Luigi Bocconi"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s12325-025-03186-8","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T10:37:01Z","timestamp":1744799821000},"page":"2606-2638","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Regional Citrate Anticoagulation Versus Systemic Heparin in Continuous Kidney Replacement Therapy: Examining the Role of Evidence in Health Technology Assessment"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6330-0591","authenticated-orcid":false,"given":"Carla","family":"Rognoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Pohlmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Tarricone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"3186_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-021-00284-z","volume":"7","author":"JA Kellum","year":"2021","unstructured":"Kellum JA, Romagnani P, Ashuntantang G, Ronco C, Zarbock A, Anders H-J. Acute kidney injury. Nat Rev Dis Primer. 2021;7:1\u201317.","journal-title":"Nat Rev Dis Primer"},{"key":"3186_CR2","doi-asserted-by":"publisher","first-page":"e250","DOI":"10.1097\/MAT.0000000000001928","volume":"69","author":"D Treu","year":"2023","unstructured":"Treu D, Ashenuga M, Massingham K, Brugger J, Medina L, Ficociello LH, et al. An innovative approach to minimizing downtime in continuous kidney replacement therapy. Asaio J. 2023;69:e250\u20135.","journal-title":"Asaio J"},{"key":"3186_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jama.2020.18618","volume":"324","author":"A Zarbock","year":"2020","unstructured":"Zarbock A, K\u00fcllmar M, Kindgen-Milles D, Wempe C, Gerss J, Brandenburger T, et al. Effect of regional citrate anticoagulation vs systemic heparin anticoagulation during continuous kidney replacement therapy on dialysis filter life span and mortality among critically ill patients with acute kidney injury. JAMA. 2020;324:1\u201311.","journal-title":"JAMA"},{"key":"3186_CR4","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/0300-2977(96)00005-8","volume":"48","author":"MJFM Janssen","year":"1996","unstructured":"Janssen MJFM, van der Meulen J. The bleeding risk in chronic haemodialysis: preventive strategies in high-risk patients. Neth J Med. 1996;48:198\u2013207.","journal-title":"Neth J Med"},{"key":"3186_CR5","unstructured":"Acute Kidney Injury (AKI)\u2014KDIGO. [cited 2023 Nov 20]. https:\/\/kdigo.org\/guidelines\/acute-kidney-injury\/."},{"key":"3186_CR6","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s13054-016-1299-0","volume":"20","author":"C Liu","year":"2016","unstructured":"Liu C, Mao Z, Kang H, Hu J, Zhou F. Regional citrate versus heparin anticoagulation for continuous renal replacement therapy in critically ill patients: a meta-analysis with trial sequential analysis of randomized controlled trials. Crit Care Lond Engl. 2016;20:144.","journal-title":"Crit Care Lond Engl"},{"key":"3186_CR7","first-page":"982","volume":"32","author":"X Feng","year":"2020","unstructured":"Feng X, Deng L, Zhang Y, Chang L. Regional citrate versus heparin anticoagulation in continuous renal replacement therapy in critically ill patients: a meta-analysis. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020;32:982\u20137.","journal-title":"Zhonghua Wei Zhong Bing Ji Jiu Yi Xue"},{"key":"3186_CR8","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.2215\/CJN.01280214","volume":"9","author":"S Morabito","year":"2014","unstructured":"Morabito S, Pistolesi V, Tritapepe L, Fiaccadori E. Regional citrate anticoagulation for RRTs in critically ill patients with AKI. Clin J Am Soc Nephrol CJASN. 2014;9:2173\u201388.","journal-title":"Clin J Am Soc Nephrol CJASN"},{"key":"3186_CR9","unstructured":"Khadzhynov D, Slowinski T, Schreiber A, Lieker I, Halleck F, Lehner LJ, et al. Recurrent early filter clotting during continuous veno-venous hemodialysis with regional citrate anticoagulation is linked to systemic thrombin generation and heparin induced thrombocytopenia type II: a retrospective analysis. [cited 2025 Feb 18]. https:\/\/austinpublishinggroup.com\/critical-care-case-reports\/fulltext\/criticalcarecr-v5-id1032.php."},{"key":"3186_CR10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1186\/cc11645","volume":"16","author":"HM Oudemans-van Straaten","year":"2012","unstructured":"Oudemans-van Straaten HM, Ostermann M. Bench-to-bedside review: citrate for continuous renal replacement therapy, from science to practice. Crit Care. 2012;16:249. https:\/\/doi.org\/10.1186\/cc11645.","journal-title":"Crit Care"},{"key":"3186_CR11","first-page":"439","volume":"2","author":"A Davenport","year":"2009","unstructured":"Davenport A, Tolwani A. Citrate anticoagulation for continuous renal replacement therapy (CRRT) in patients with acute kidney injury admitted to the intensive care unit. NDT Plus. 2009;2:439\u201347.","journal-title":"NDT Plus"},{"key":"3186_CR12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s44158-023-00091-w","volume":"3","author":"V Pistolesi","year":"2023","unstructured":"Pistolesi V, Morabito S, Pota V, Valente F, Di Mario F, Fiaccadori E, et al. Regional citrate anticoagulation (RCA) in critically ill patients undergoing renal replacement therapy (RRT): expert opinion from the SIAARTI-SIN joint commission. J Anesth Analg Crit Care. 2023;3:7. https:\/\/doi.org\/10.1186\/s44158-023-00091-w.","journal-title":"J Anesth Analg Crit Care."},{"key":"3186_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/ZXHI9396","volume":"26","author":"DW Gould","year":"2022","unstructured":"Gould DW, Doidge J, Sadique MZ, Borthwick M, Hatch R, Caskey FJ, et al. Heparin versus citrate anticoagulation for continuous renal replacement therapy in intensive care: the RRAM observational study. Health Technol Assess Winch Engl. 2022;26:1\u201358.","journal-title":"Health Technol Assess Winch Engl"},{"key":"3186_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2022.154218","volume":"74","author":"JC Doidge","year":"2023","unstructured":"Doidge JC, Gould DW, Sadique Z, Borthwick M, Hatch RA, Caskey FJ, et al. Regional citrate anticoagulation versus systemic heparin anticoagulation for continuous kidney replacement therapy in intensive care. J Crit Care. 2023;74: 154218.","journal-title":"J Crit Care"},{"key":"3186_CR15","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1183\/16000617.0016-2016","volume":"25","author":"R Tarricone","year":"2016","unstructured":"Tarricone R, Boscolo PR, Armeni P. What type of clinical evidence is needed to assess medical devices? Eur Respir Rev Off J Eur Respir Soc. 2016;25:259\u201365.","journal-title":"Eur Respir Rev Off J Eur Respir Soc"},{"key":"3186_CR16","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.","journal-title":"BMJ"},{"key":"3186_CR17","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s40620-020-00794-1","volume":"33","author":"G Quintaliani","year":"2020","unstructured":"Quintaliani G, Reboldi G, Di Napoli A, Nordio M, Limido A, Aucella F, et al. Exposure to novel coronavirus in patients on renal replacement therapy during the exponential phase of COVID-19 pandemic: survey of the Italian Society of Nephrology. J Nephrol. 2020;33:725\u201336. https:\/\/doi.org\/10.1007\/s40620-020-00794-1.","journal-title":"J Nephrol"},{"key":"3186_CR18","first-page":"210","volume":"45","author":"PDV Teichmann","year":"2023","unstructured":"Teichmann PDV, Moschetta MO, Franco RF, Vicari AR, Nunes GLDS, Lazzaretti MAKN, et al. One-year impact of COVID-19 pandemic on renal replacement therapy and kidney transplantation in a tertiary center in Southern Brazil. J Bras Nefrol. 2023;45:210\u20137.","journal-title":"J Bras Nefrol"},{"key":"3186_CR19","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1097\/00003246-199910000-00026","volume":"27","author":"JH Reeves","year":"1999","unstructured":"Reeves JH, Cumming AR, Gallagher L, O\u2019Brien JL, Santamaria JD. A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. Crit Care Med. 1999;27:2224\u20138.","journal-title":"Crit Care Med"},{"key":"3186_CR20","first-page":"CD012467","volume":"12","author":"H Tsujimoto","year":"2020","unstructured":"Tsujimoto H, Tsujimoto Y, Nakata Y, Fujii T, Takahashi S, Akazawa M, et al. Pharmacological interventions for preventing clotting of extracorporeal circuits during continuous renal replacement therapy. Cochrane Database Syst Rev. 2020;12:CD012467.","journal-title":"Cochrane Database Syst Rev"},{"key":"3186_CR21","first-page":"ED000142","volume":"10","author":"M Cumpston","year":"2019","unstructured":"Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019;10:ED000142.","journal-title":"Cochrane Database Syst Rev"},{"key":"3186_CR22","unstructured":"Bank EC. ECB\/Eurosystem policy and exchange rates. 2022 [cited 2024 Feb 27]. https:\/\/www.ecb.europa.eu\/stats\/policy_and_exchange_rates\/html\/index.en.html."},{"key":"3186_CR23","unstructured":"Istat\u2014rivaluta. [cited 2024 Feb 27]. https:\/\/rivaluta.istat.it\/."},{"key":"3186_CR24","unstructured":"Cochrane handbook for systematic reviews of interventions. [cited 2023 Dec 28]. https:\/\/training.cochrane.org\/handbook\/current."},{"key":"3186_CR25","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1673\/031.003.3401","volume":"3","author":"ME Payton","year":"2003","unstructured":"Payton ME, Greenstone MH, Schenker N. Overlapping confidence intervals or standard error intervals: what do they mean in terms of statistical significance? J Insect Sci. 2003;3:34.","journal-title":"J Insect Sci"},{"key":"3186_CR26","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924\u20136. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD.","journal-title":"BMJ"},{"key":"3186_CR27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jclinepi.2023.05.010","volume":"159","author":"HJ Sch\u00fcnemann","year":"2023","unstructured":"Sch\u00fcnemann HJ, Brennan S, Akl EA, Hultcrantz M, Alonso-Coello P, Xia J, et al. The development methods of official GRADE articles and requirements for claiming the use of GRADE\u2014a statement by the GRADE guidance group. J Clin Epidemiol. 2023;159:79\u201384.","journal-title":"J Clin Epidemiol"},{"key":"3186_CR28","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/S0272-6386(00)70248-4","volume":"35","author":"DJ Kutsogiannis","year":"2000","unstructured":"Kutsogiannis DJ, Mayers I, Chin WD, Gibney RT. Regional citrate anticoagulation in continuous venovenous hemodiafiltration. Am J Kidney Dis Off J Natl Kidney Found. 2000;35:802\u201311.","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"3186_CR29","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1046\/j.1523-1755.2001.00809.x","volume":"60","author":"AJ Tolwani","year":"2001","unstructured":"Tolwani AJ, Campbell RC, Schenk MB, Allon M, Warnock DG. Simplified citrate anticoagulation for continuous renal replacement therapy. Kidney Int. 2001;60:370\u20134.","journal-title":"Kidney Int"},{"key":"3186_CR30","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s00134-002-1443-y","volume":"28","author":"L Gabutti","year":"2002","unstructured":"Gabutti L, Marone C, Colucci G, Duchini F, Sch\u00f6nholzer C. Citrate anticoagulation in continuous venovenous hemodiafiltration: a metabolic challenge. Intensive Care Med. 2002;28:1419\u201325.","journal-title":"Intensive Care Med"},{"key":"3186_CR31","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1081\/JDI-120005366","volume":"24","author":"RM Hofmann","year":"2002","unstructured":"Hofmann RM, Maloney C, Ward DM, Becker BN. A novel method for regional citrate anticoagulation in continuous venovenous hemofiltration (CVVHF). Ren Fail. 2002;24:325\u201335.","journal-title":"Ren Fail"},{"key":"3186_CR32","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1053\/jcrc.2003.50006","volume":"18","author":"SW Tobe","year":"2003","unstructured":"Tobe SW, Aujla P, Walele AA, Oliver MJ, Naimark DMJ, Perkins NJ, et al. A novel regional citrate anticoagulation protocol for CRRT using only commercially available solutions. J Crit Care. 2003;18:121\u20139.","journal-title":"J Crit Care"},{"key":"3186_CR33","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1007\/s00134-003-2047-x","volume":"30","author":"M Monchi","year":"2004","unstructured":"Monchi M, Berghmans D, Ledoux D, Canivet J-L, Dubois B, Damas P. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. Intensive Care Med. 2004;30:260\u20135.","journal-title":"Intensive Care Med"},{"key":"3186_CR34","doi-asserted-by":"publisher","first-page":"c131","DOI":"10.1159\/000079171","volume":"97","author":"S Morgera","year":"2004","unstructured":"Morgera S, Scholle C, Voss G, Haase M, Vargas-Hein O, Krausch D, et al. Metabolic complications during regional citrate anticoagulation in continuous venovenous hemodialysis: single-center experience. Nephron Clin Pract. 2004;97:c131-136.","journal-title":"Nephron Clin Pract"},{"key":"3186_CR35","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1159\/000087770","volume":"23","author":"M Balik","year":"2005","unstructured":"Balik M, Waldauf P, Pl\u00e1sil P, Pachl J. Prostacyclin versus citrate in continuous haemodiafiltration: an observational study in patients with high risk of bleeding. Blood Purif. 2005;23:325\u20139.","journal-title":"Blood Purif"},{"key":"3186_CR36","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1053\/j.ajkd.2005.08.010","volume":"46","author":"A Bihorac","year":"2005","unstructured":"Bihorac A, Ross EA. Continuous venovenous hemofiltration with citrate-based replacement fluid: efficacy, safety, and impact on nutrition. Am J Kidney Dis Off J Natl Kidney Found. 2005;46:908\u201318.","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"3186_CR37","first-page":"1416","volume":"20","author":"PD Brophy","year":"2005","unstructured":"Brophy PD, Somers MJG, Baum MA, Symons JM, McAfee N, Fortenberry JD, et al. Multi-centre evaluation of anticoagulation in patients receiving continuous renal replacement therapy (CRRT). Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc Eur Ren Assoc. 2005;20:1416\u201321.","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc Eur Ren Assoc"},{"key":"3186_CR38","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1080\/08860220500198748","volume":"27","author":"KW Finkel","year":"2005","unstructured":"Finkel KW, Foringer JR. Safety of regional citrate anticoagulation for continuous sustained low efficiency dialysis (C-SLED) in critically ill patients. Ren Fail. 2005;27:541\u20135.","journal-title":"Ren Fail"},{"key":"3186_CR39","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1111\/j.1523-1755.2005.00342.x","volume":"67","author":"DJ Kutsogiannis","year":"2005","unstructured":"Kutsogiannis DJ, Gibney RTN, Stollery D, Gao J. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int. 2005;67:2361\u20137.","journal-title":"Kidney Int"},{"key":"3186_CR40","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1177\/0310057X0503300509","volume":"33","author":"T Naka","year":"2005","unstructured":"Naka T, Egi M, Bellomo R, Cole L, French C, Botha J, et al. Commercial low-citrate anticoagulation haemofiltration in high risk patients with frequent filter clotting. Anaesth Intensive Care. 2005;33:601\u20138.","journal-title":"Anaesth Intensive Care"},{"key":"3186_CR41","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1440-1797.2006.00653.x","volume":"11","author":"S Munjal","year":"2006","unstructured":"Munjal S, Ejaz AA. Regional citrate anticoagulation in continuous venovenous haemofiltration using commercial preparations. Nephrol Carlton Vic. 2006;11:405\u20139.","journal-title":"Nephrol Carlton Vic"},{"key":"3186_CR42","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1177\/039139880602900603","volume":"29","author":"PHJ Van der Voort","year":"2006","unstructured":"Van der Voort PHJ, Postma SR, Kingma WP, Boerma EC, Van Roon EN. Safety of citrate based hemofiltration in critically ill patients at high risk for bleeding: a comparison with nadroparin. Int J Artif Organs. 2006;29:559\u201363.","journal-title":"Int J Artif Organs"},{"key":"3186_CR43","first-page":"602","volume":"20","author":"MGH Betjes","year":"2007","unstructured":"Betjes MGH, van Oosterom D, van Agteren M, van de Wetering J. Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. J Nephrol. 2007;20:602\u20138.","journal-title":"J Nephrol"},{"key":"3186_CR44","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1177\/039139880703000310","volume":"30","author":"L Cubattoli","year":"2007","unstructured":"Cubattoli L, Teruzzi M, Cormio M, Lampati L, Pesenti A. Citrate anticoagulation during CVVH in high risk bleeding patients. Int J Artif Organs. 2007;30:244\u201352.","journal-title":"Int J Artif Organs"},{"key":"3186_CR45","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/039139880703000404","volume":"30","author":"N Fealy","year":"2007","unstructured":"Fealy N, Baldwin I, Johnstone M, Egi M, Bellomo R. A pilot randomized controlled crossover study comparing regional heparinization to regional citrate anticoagulation for continuous venovenous hemofiltration. Int J Artif Organs. 2007;30:301\u20137.","journal-title":"Int J Artif Organs"},{"key":"3186_CR46","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1159\/000107045","volume":"25","author":"SA Nurmohamed","year":"2007","unstructured":"Nurmohamed SA, Vervloet MG, Girbes ARJ, Ter Wee PM, Groeneveld ABJ. Continuous venovenous hemofiltration with or without predilution regional citrate anticoagulation: a prospective study. Blood Purif. 2007;25:316\u201323.","journal-title":"Blood Purif"},{"key":"3186_CR47","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1007\/s00134-007-0754-4","volume":"33","author":"S Uchino","year":"2007","unstructured":"Uchino S, Bellomo R, Morimatsu H, Morgera S, Schetz M, Tan I, et al. Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators. Intensive Care Med. 2007;33:1563\u201370.","journal-title":"Intensive Care Med"},{"key":"3186_CR48","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1177\/039139880803101103","volume":"31","author":"T Cassina","year":"2008","unstructured":"Cassina T, Mauri R, Engeler A, Giannini O. Continuous veno-venous hemofiltration with regional citrate anticoagulation: a four-year single-center experience. Int J Artif Organs. 2008;31:937\u201343.","journal-title":"Int J Artif Organs"},{"key":"3186_CR49","doi-asserted-by":"publisher","first-page":"3024","DOI":"10.1097\/CCM.0b013e31818b9100","volume":"36","author":"MS Dur\u00e3o","year":"2008","unstructured":"Dur\u00e3o MS, Monte JCM, Batista MC, Oliveira M, Iizuka IJ, Santos BF, et al. The use of regional citrate anticoagulation for continuous venovenous hemodiafiltration in acute kidney injury. Crit Care Med. 2008;36:3024\u20139.","journal-title":"Crit Care Med"},{"key":"3186_CR50","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1345\/aph.1M182","volume":"43","author":"LD Burry","year":"2009","unstructured":"Burry LD, Tung DD, Hallett D, Bailie T, Carvalhana V, Lee D, et al. Regional citrate anticoagulation for PrismaFlex continuous renal replacement therapy. Ann Pharmacother. 2009;43:1419\u201325.","journal-title":"Ann Pharmacother"},{"key":"3186_CR51","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1097\/CCM.0b013e3181a00a92","volume":"37","author":"S Morgera","year":"2009","unstructured":"Morgera S, Schneider M, Slowinski T, Vargas-Hein O, Zuckermann-Becker H, Peters H, et al. A safe citrate anticoagulation protocol with variable treatment efficacy and excellent control of the acid-base status. Crit Care Med. 2009;37:2018\u201324.","journal-title":"Crit Care Med"},{"key":"3186_CR52","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1097\/CCM.0b013e3181953c5e","volume":"37","author":"HM Oudemans-van Straaten","year":"2009","unstructured":"Oudemans-van Straaten HM, Bosman RJ, Koopmans M, van der Voort PHJ, Wester JPJ, van der Spoel JI, et al. Citrate anticoagulation for continuous venovenous hemofiltration. Crit Care Med. 2009;37:545\u201352.","journal-title":"Crit Care Med"},{"key":"3186_CR53","first-page":"232","volume":"26","author":"GR Hetzel","year":"2011","unstructured":"Hetzel GR, Schmitz M, Wissing H, Ries W, Schott G, Heering PJ, et al. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2011;26:232\u20139.","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc"},{"key":"3186_CR54","doi-asserted-by":"publisher","first-page":"68","DOI":"10.3904\/kjim.2011.26.1.68","volume":"26","author":"J-S Park","year":"2011","unstructured":"Park J-S, Kim G-H, Kang CM, Lee CH. Regional anticoagulation with citrate is superior to systemic anticoagulation with heparin in critically ill patients undergoing continuous venovenous hemodiafiltration. Korean J Intern Med. 2011;26:68\u201375.","journal-title":"Korean J Intern Med"},{"key":"3186_CR55","first-page":"556","volume":"15","author":"K Tiranathanagul","year":"2011","unstructured":"Tiranathanagul K, Jearnsujitwimol O, Susantitaphong P, Kijkriengkraikul N, Leelahavanichkul A, Srisawat N, et al. Regional citrate anticoagulation reduces polymorphonuclear cell degranulation in critically ill patients treated with continuous venovenous hemofiltration. Ther Apher Dial Off Peer-Rev J Int Soc Apher Jpn Soc Apher Jpn Soc Dial Ther. 2011;15:556\u201364.","journal-title":"Ther Apher Dial Off Peer-Rev J Int Soc Apher Jpn Soc Apher Jpn Soc Dial Ther"},{"key":"3186_CR56","doi-asserted-by":"publisher","first-page":"R97","DOI":"10.1186\/cc11363","volume":"16","author":"A Link","year":"2012","unstructured":"Link A, Klingele M, Speer T, Rbah R, P\u00f6ss J, Lerner-Gr\u00e4ber A, et al. Total-to-ionized calcium ratio predicts mortality in continuous renal replacement therapy with citrate anticoagulation in critically ill patients. Crit Care Lond Engl. 2012;16:R97.","journal-title":"Crit Care Lond Engl"},{"key":"3186_CR57","doi-asserted-by":"publisher","first-page":"R111","DOI":"10.1186\/cc11403","volume":"16","author":"S Morabito","year":"2012","unstructured":"Morabito S, Pistolesi V, Tritapepe L, Zeppilli L, Polistena F, Strampelli E, et al. Regional citrate anticoagulation in cardiac surgery patients at high risk of bleeding: a continuous veno-venous hemofiltration protocol with a low concentration citrate solution. Crit Care Lond Engl. 2012;16:R111.","journal-title":"Crit Care Lond Engl"},{"key":"3186_CR58","first-page":"1651","volume":"27","author":"FH Saner","year":"2012","unstructured":"Saner FH, Treckmann JW, Geis A, L\u00f6sch C, Witzke O, Canbay A, et al. Efficacy and safety of regional citrate anticoagulation in liver transplant patients requiring post-operative renal replacement therapy. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc Eur Ren Assoc. 2012;27:1651\u20137.","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc Eur Ren Assoc"},{"key":"3186_CR59","first-page":"202","volume":"17","author":"R Kalb","year":"2013","unstructured":"Kalb R, Kram R, Morgera S, Slowinski T, Kindgen-Milles D. Regional citrate anticoagulation for high volume continuous venovenous hemodialysis in surgical patients with high bleeding risk. Ther Apher Dial Off Peer-Rev J Int Soc Apher Jpn Soc Apher Jpn Soc Dial Ther. 2013;17:202\u201312.","journal-title":"Ther Apher Dial Off Peer-Rev J Int Soc Apher Jpn Soc Apher Jpn Soc Dial Ther"},{"key":"3186_CR60","first-page":"349512","volume":"2013","author":"AK-H Leung","year":"2013","unstructured":"Leung AK-H, Shum H-P, Chan K-C, Chan SC-H, Lai KY, Yan W-W. A retrospective review of the use of regional citrate anticoagulation in continuous venovenous hemofiltration for critically ill patients. Crit Care Res Pract. 2013;2013:349512.","journal-title":"Crit Care Res Pract."},{"key":"3186_CR61","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1159\/000355860","volume":"124","author":"M Raimundo","year":"2013","unstructured":"Raimundo M, Crichton S, Lei K, Sanderson B, Smith J, Brooks J, et al. Maintaining normal levels of ionized calcium during citrate-based renal replacement therapy is associated with stable parathyroid hormone levels. Nephron Clin Pract. 2013;124:124\u201331.","journal-title":"Nephron Clin Pract"},{"key":"3186_CR62","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000355550","volume":"124","author":"L Tovey","year":"2013","unstructured":"Tovey L, Dickie H, Gangi S, Terblanche M, McKenzie C, Beale R, et al. Beyond the randomized clinical trial: citrate for continuous renal replacement therapy in clinical practice. Nephron Clin Pract. 2013;124:119\u201323.","journal-title":"Nephron Clin Pract"},{"key":"3186_CR63","first-page":"131","volume":"16","author":"MJ Brain","year":"2014","unstructured":"Brain MJ, Roodenburg OS, Adams N, McCracken P, Hockings L, Musgrave S, et al. Randomised trial of software algorithm-driven regional citrate anticoagulation versus heparin in continuous renal replacement therapy: the filter life in renal replacement therapy pilot trial. Crit Care Resusc. 2014;16:131\u201342.","journal-title":"Crit Care Resusc"},{"key":"3186_CR64","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/hdi.12157","volume":"18","author":"RCD Granado","year":"2014","unstructured":"Granado RCD, Macedo E, Soroko S, Kim Y, Chertow GM, Himmelfarb J, et al. Anticoagulation, delivered dose and outcomes in CRRT: the program to improve care in acute renal disease (PICARD). Hemodial Int Int Symp Home Hemodial. 2014;18:641\u20139.","journal-title":"Hemodial Int Int Symp Home Hemodial."},{"key":"3186_CR65","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jcrc.2013.10.015","volume":"29","author":"D Khadzhynov","year":"2014","unstructured":"Khadzhynov D, Schelter C, Lieker I, Mika A, Staeck O, Neumayer H-H, et al. Incidence and outcome of metabolic disarrangements consistent with citrate accumulation in critically ill patients undergoing continuous venovenous hemodialysis with regional citrate anticoagulation. J Crit Care. 2014;29:265\u201371.","journal-title":"J Crit Care"},{"key":"3186_CR66","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1186\/s13054-014-0472-6","volume":"18","author":"L Schilder","year":"2014","unstructured":"Schilder L, Nurmohamed SA, Bosch FH, Purmer IM, den Boer SS, Kleppe CG, et al. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Crit Care Lond Engl. 2014;18:472.","journal-title":"Crit Care Lond Engl"},{"key":"3186_CR67","first-page":"413","volume":"60","author":"H Shum","year":"2014","unstructured":"Shum H, Kwan AM-C, Chan K-C, Yan W-W. The use of regional citrate anticoagulation continuous venovenous hemofiltration in extracorporeal membrane oxygenation. ASAIO J Am Soc Artif Intern Organs. 2014;60:413\u20138.","journal-title":"ASAIO J Am Soc Artif Intern Organs."},{"key":"3186_CR68","doi-asserted-by":"publisher","first-page":"e808320","DOI":"10.1155\/2014\/808320","volume":"2014","author":"C Sponholz","year":"2014","unstructured":"Sponholz C, Bayer O, Kabisch B, Wurm K, Ebert K, Bauer M, et al. Anticoagulation strategies in venovenous hemodialysis in critically ill patients: a five-year evaluation in a surgical intensive care unit. Sci World J. 2014;2014:e808320.","journal-title":"Sci World J"},{"key":"3186_CR69","first-page":"272","volume":"19","author":"P De Vico","year":"2015","unstructured":"De Vico P, Messino V, Tartaglione A, Beccaris C, Buonomo C, Talarico D, et al. Safety and efficacy of citrate anti-coagulation continuous renal replacement therapies in post-cardiac surgery patients with liver dysfunction. Ther Apher Dial Off Peer-Rev J Int Soc Apher Jpn Soc Apher Jpn Soc Dial Ther. 2015;19:272\u20138.","journal-title":"Ther Apher Dial Off Peer-Rev J Int Soc Apher Jpn Soc Apher Jpn Soc Dial Ther"},{"key":"3186_CR70","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1097\/CCM.0000000000001004","volume":"43","author":"DJ Gattas","year":"2015","unstructured":"Gattas DJ, Rajbhandari D, Bradford C, Buhr H, Lo S, Bellomo R. A randomized controlled trial of regional citrate versus regional heparin anticoagulation for continuous renal replacement therapy in critically ill adults. Crit Care Med. 2015;43:1622\u20139.","journal-title":"Crit Care Med"},{"key":"3186_CR71","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s40560-015-0102-7","volume":"3","author":"S Hafner","year":"2015","unstructured":"Hafner S, Stahl W, Fels T, Tr\u00e4ger K, Georgieff M, Wepler M. Implementation of continuous renal replacement therapy with regional citrate anticoagulation on a surgical and trauma intensive care unit: impact on clinical and economic aspects-an observational study. J Intensive Care. 2015;3:35.","journal-title":"J Intensive Care"},{"key":"3186_CR72","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1186\/s13054-015-1066-7","volume":"19","author":"T Slowinski","year":"2015","unstructured":"Slowinski T, Morgera S, Joannidis M, Henneberg T, Stocker R, Helset E, et al. Safety and efficacy of regional citrate anticoagulation in continuous venovenous hemodialysis in the presence of liver failure: the liver citrate anticoagulation threshold (L-CAT) observational study. Crit Care Lond Engl. 2015;19:349.","journal-title":"Crit Care Lond Engl"},{"key":"3186_CR73","first-page":"8","volume":"19","author":"C Sponholz","year":"2015","unstructured":"Sponholz C, Settmacher U, Bauer M, Kortgen A. Regional citrate anticoagulation for continuous renal replacement therapy in the perioperative care of liver transplant recipients: a single center experience. Ther Apher Dial Off Peer-Rev J Int Soc Apher Jpn Soc Apher Jpn Soc Dial Ther. 2015;19:8\u201315.","journal-title":"Ther Apher Dial Off Peer-Rev J Int Soc Apher Jpn Soc Apher Jpn Soc Dial Ther"},{"key":"3186_CR74","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13054-015-0822-z","volume":"19","author":"F Stucker","year":"2015","unstructured":"Stucker F, Ponte B, Tataw J, Martin P-Y, Wozniak H, Pugin J, et al. Efficacy and safety of citrate-based anticoagulation compared to heparin in patients with acute kidney injury requiring continuous renal replacement therapy: a randomized controlled trial. Crit Care Lond Engl. 2015;19:91.","journal-title":"Crit Care Lond Engl"},{"key":"3186_CR75","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1159\/000381662","volume":"39","author":"B Wu","year":"2015","unstructured":"Wu B, Zhang K, Xu B, Ji D, Liu Z, Gong D. Randomized controlled trial to evaluate regional citrate anticoagulation plus low-dose of dalteparin in continuous veno-venous hemofiltration. Blood Purif. 2015;39:306\u201312.","journal-title":"Blood Purif"},{"key":"3186_CR76","first-page":"53","volume":"20","author":"D Gutierrez-Bernays","year":"2016","unstructured":"Gutierrez-Bernays D, Ostwald M, Anstey C, Campbell V. Transition from heparin to citrate anticoagulation for continuous renal replacement therapy: safety, efficiency, and cost. Ther Apher Dial Off Peer-Rev J Int Soc Apher Jpn Soc Apher Jpn Soc Dial Ther. 2016;20:53\u20139.","journal-title":"Ther Apher Dial Off Peer-Rev J Int Soc Apher Jpn Soc Apher Jpn Soc Dial Ther"},{"key":"3186_CR77","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.iccn.2016.04.001","volume":"36","author":"M Houll\u00e9-Veyssi\u00e8re","year":"2016","unstructured":"Houll\u00e9-Veyssi\u00e8re M, Courtin A, Zeroual N, Gaudard P, Colson PH. Continuous venovenous renal replacement therapy in critically ill patients: a work load analysis. Intensive Crit Care Nurs. 2016;36:35\u201341.","journal-title":"Intensive Crit Care Nurs"},{"key":"3186_CR78","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1177\/1751143717695835","volume":"18","author":"R Borg","year":"2017","unstructured":"Borg R, Ugboma D, Walker D-M, Partridge R. Evaluating the safety and efficacy of regional citrate compared to systemic heparin as anticoagulation for continuous renal replacement therapy in critically ill patients: a service evaluation following a change in practice. J Intensive Care Soc. 2017;18:184\u201392.","journal-title":"J Intensive Care Soc."},{"key":"3186_CR79","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1177\/1751143716676820","volume":"18","author":"SR Chowdhury","year":"2017","unstructured":"Chowdhury SR, Lawton T, Akram A, Collin R, Beck J. Citrate versus non-citrate anticoagulation in continuous renal replacement therapy: Results following a change in local critical care protocol. J Intensive Care Soc. 2017;18:47\u201351.","journal-title":"J Intensive Care Soc."},{"key":"3186_CR80","unstructured":"Dalhuisen A, Vogtl\u00e4nder N, Katinakis A, Steenbergen H, Kamphuis S, Spronk P. Comparing CVVH with CVVHD during citrate anticoagulation in ICU patients. 2017 [cited 2023 Dec 28]. https:\/\/www.semanticscholar.org\/paper\/Comparing-CVVH-with-CVVHD-during-citrate-in-ICU-Dalhuisen-Vogtl%C3%A4nder\/a7638d3d49eb80d63868e5c3765df64652681f70."},{"key":"3186_CR81","doi-asserted-by":"publisher","first-page":"676","DOI":"10.5301\/ijao.5000633","volume":"40","author":"M Huguet","year":"2017","unstructured":"Huguet M, Rodas L, Blasco M, Quintana LF, Mercadal J, Ortiz-P\u00e9rez JT, et al. Clinical impact of regional citrate anticoagulation in continuous renal replacement therapy in critically ill patients. Int J Artif Organs. 2017;40:676\u201382.","journal-title":"Int J Artif Organs"},{"key":"3186_CR82","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1159\/000451053","volume":"43","author":"P Schl\u00e4pfer","year":"2017","unstructured":"Schl\u00e4pfer P, Durovray J-D, Plouhinec V, Chiappa C, Bellomo R, Schneider A. A first evaluation of OMNI\u00ae, a new device for continuous renal replacement therapy. Blood Purif. 2017;43:11\u20137.","journal-title":"Blood Purif"},{"key":"3186_CR83","doi-asserted-by":"publisher","DOI":"10.1590\/1414-431x20176378","volume":"51","author":"B Tuerdi","year":"2017","unstructured":"Tuerdi B, Zuo L, Sun H, Wang K, Wang Z, Li G. Safety and efficacy of regional citrate anticoagulation in continuous blood purification treatment of patients with multiple organ dysfunction syndrome. Braz J Med Biol Res Rev Bras Pesqui Medicas E Biol. 2017;51: e6378.","journal-title":"Braz J Med Biol Res Rev Bras Pesqui Medicas E Biol"},{"key":"3186_CR84","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1177\/0310057X18824596","volume":"47","author":"CU Dissanayake","year":"2019","unstructured":"Dissanayake CU, Bharat CI, Roberts BL, Anstey MH. A cost comparison of regional citrate versus low-dose systemic heparin anticoagulation in continuous renal replacement therapy. Anaesth Intensive Care. 2019;47:281\u20137.","journal-title":"Anaesth Intensive Care"},{"key":"3186_CR85","doi-asserted-by":"publisher","first-page":"6607","DOI":"10.1038\/s41598-019-42916-1","volume":"9","author":"J Gao","year":"2019","unstructured":"Gao J, Wang F, Wang Y, Jin D, Tang L, Pan K. A mode of CVVH with regional citrate anticoagulation compared to no anticoagulation for acute kidney injury patients at high risk of bleeding. Sci Rep. 2019;9:6607.","journal-title":"Sci Rep"},{"key":"3186_CR86","doi-asserted-by":"publisher","first-page":"NP19","DOI":"10.1177\/1751143719840258","volume":"20","author":"N Zeroual","year":"2019","unstructured":"Zeroual N, Gaudard P, Colson PH. Costs difference between hemodiafiltration with unfractionated heparin versus hemodialysis with regional citrate anticoagulation. J Intensive Care Soc. 2019;20:NP19\u201320.","journal-title":"J Intensive Care Soc."},{"key":"3186_CR87","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/MAT.0000000000001003","volume":"66","author":"M Giani","year":"2020","unstructured":"Giani M, Scaravilli V, Stefanini F, Valsecchi G, Rona R, Grasselli G, et al. Continuous renal replacement therapy in venovenous extracorporeal membrane oxygenation: a retrospective study on regional citrate anticoagulation. ASAIO J. 2020;66:332.","journal-title":"ASAIO J"},{"key":"3186_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jcrc.2020.03.002","volume":"58","author":"D Khadzhynov","year":"2020","unstructured":"Khadzhynov D, Deissler J, Bobonov O, Schelter C, Peters H, Kindgen-Milles D, et al. Intensive monitoring of post filter ionized calcium concentrations during CVVHD with regional citrate anticoagulation: a retrospective study. J Crit Care. 2020;58:1\u20135.","journal-title":"J Crit Care"},{"key":"3186_CR89","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1111\/sdi.12923","volume":"34","author":"L Li","year":"2020","unstructured":"Li L, Bai M, Yu Y, Li Y, Zhao L, Sun S. Regional citrate anticoagulation vs no-anticoagulation for CRRT in hyperlactatemia patients with increased bleeding risk: a retrospective cohort study. Semin Dial. 2020;34:209\u201317.","journal-title":"Semin Dial"},{"key":"3186_CR90","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1159\/000529076","volume":"52","author":"R Ratanarat","year":"2023","unstructured":"Ratanarat R, Phairatwet P, Khansompop S, Naorungroj T. Customized citrate anticoagulation versus no anticoagulant in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a prospective randomized controlled trial. Blood Purif. 2023;52:455\u201363.","journal-title":"Blood Purif"},{"key":"3186_CR91","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1080\/0886022X.2020.1795879","volume":"42","author":"Y Yu","year":"2020","unstructured":"Yu Y, Bai M, Wei Z, Zhao L, Li Y, Ma F, et al. Regional citrate anticoagulation versus low molecular weight heparin anticoagulation for continuous venovenous hemofiltration in patients with severe hypercalcemia: a retrospective cohort study. Ren Fail. 2020;42:748\u201358.","journal-title":"Ren Fail"},{"key":"3186_CR92","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232516","volume":"15","author":"Y Yu","year":"2020","unstructured":"Yu Y, Bai M, Ma F, Zhang W, Li Y, Zhao L, et al. Regional citrate anticoagulation versus no-anticoagulation for continuous venovenous hemofiltration in patients with liver failure and increased bleeding risk: a retrospective case-control study. PLoS ONE. 2020;15: e0232516.","journal-title":"PLoS ONE"},{"key":"3186_CR93","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000502937","volume":"49","author":"L Zhao","year":"2020","unstructured":"Zhao L, Ma F, Yu Y, Li Y, Wang Y, He L, et al. Regional citrate anticoagulation versus no-anticoagulation for continuous venovenous hemofiltration in acute severe hypernatremia patients with increased bleeding risk: a retrospective cohort study. Blood Purif. 2020;49:44\u201354.","journal-title":"Blood Purif"},{"key":"3186_CR94","first-page":"229","volume":"15","author":"A Rabbani","year":"2021","unstructured":"Rabbani A, Dalili N, Ashrafi S, Hassanzadeh K, Aliabbar S, Nikeghbalian S, et al. Continuous renal replacement therapy with low dose systemic heparin in liver transplant recipients. Iran J Kidney Dis. 2021;15:229\u201334.","journal-title":"Iran J Kidney Dis"},{"key":"3186_CR95","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1053\/j.ajkd.2021.01.017","volume":"78","author":"H Rhee","year":"2021","unstructured":"Rhee H, Berenger B, Mehta RL, Macedo E. Regional citrate anticoagulation for continuous kidney replacement therapy with calcium-containing solutions: a cohort study. Am J Kidney Dis Off J Natl Kidney Found. 2021;78:550-559.e1.","journal-title":"Am J Kidney Dis Off J Natl Kidney Found"},{"key":"3186_CR96","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1177\/03913988211003586","volume":"45","author":"L Li","year":"2022","unstructured":"Li L, Bai M, Zhang W, Zhao L, Yu Y, Sun S. Regional citrate anticoagulation versus low molecular weight heparin for CRRT in hyperlactatemia patients: a retrospective case-control study. Int J Artif Organs. 2022;45:343\u201350.","journal-title":"Int J Artif Organs"},{"key":"3186_CR97","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10047-022-01329-0","volume":"26","author":"T Trakarnvanich","year":"2023","unstructured":"Trakarnvanich T, Sirivongrangson P, Trongtrakul K, Srisawat N. The effect of citrate in cardiovascular system and clot circuit in critically ill patients requiring continuous renal replacement therapy. J Artif Organs Off J Jpn Soc Artif Organs. 2023;26:53\u201364.","journal-title":"J Artif Organs Off J Jpn Soc Artif Organs"},{"key":"3186_CR98","first-page":"e12420","volume":"13","author":"M Tinawi","year":"2024","unstructured":"Tinawi M. Disorders of calcium metabolism: hypocalcemia and hypercalcemia. Cureus. 2024;13:e12420.","journal-title":"Cureus."},{"key":"3186_CR99","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2015","unstructured":"Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW, Drummond MF, et al. Methods for the economic evaluation of health care programmes. 4th ed. Oxford, New York: Oxford University Press; 2015.","edition":"4"},{"key":"3186_CR100","first-page":"471","volume":"22","author":"L Grudzinski","year":"2007","unstructured":"Grudzinski L, Quinan P, Kwok S, Pierratos A. Sodium citrate 4% locking solution for central venous dialysis catheters\u2013an effective, more cost-efficient alternative to heparin. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2007;22:471\u20136.","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc"},{"key":"3186_CR101","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/1472-6963-8-132","volume":"8","author":"JA Griffiths","year":"2008","unstructured":"Griffiths JA, Morgan K, Barber VS, Young JD. Study protocol: the intensive care outcome network ('ICON\u2019) study. BMC Health Serv Res. 2008;8:132.","journal-title":"BMC Health Serv Res"},{"key":"3186_CR102","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1177\/0098858818789428","volume":"44","author":"E Hall-Lipsy","year":"2018","unstructured":"Hall-Lipsy E, Barraza L, Robertson C. Practice-based research networks and the mandate for real-world evidence. Am J Law Med. 2018;44:219\u201336.","journal-title":"Am J Law Med"},{"key":"3186_CR103","unstructured":"Commissioner O of the. 21st Century Cures Act [Internet]. FDA. FDA; 2020 [cited 2023 Dec 27]. https:\/\/www.fda.gov\/regulatory-information\/selected-amendments-fdc-act\/21st-century-cures-act."},{"key":"3186_CR104","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1524-4733.2007.00186.x","volume":"10","author":"LP Garrison","year":"2007","unstructured":"Garrison LP, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health J Int Soc Pharmacoeconomics Outcomes Res. 2007;10:326\u201335.","journal-title":"Value Health J Int Soc Pharmacoeconomics Outcomes Res"},{"key":"3186_CR105","doi-asserted-by":"publisher","DOI":"10.1017\/S0266462321000301","volume":"37","author":"B Pongiglione","year":"2021","unstructured":"Pongiglione B, Torbica A, Blommestein H, de Groot S, Ciani O, Walker S, et al. Do existing real-world data sources generate suitable evidence for the HTA of medical devices in Europe? Mapping and critical appraisal. Int J Technol Assess Health Care. 2021;37: e62.","journal-title":"Int J Technol Assess Health Care"},{"key":"3186_CR106","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.jval.2017.08.3019","volume":"20","author":"ML Berger","year":"2017","unstructured":"Berger ML, Sox H, Willke RJ, Brixner DL, Eichler H-G, Goettsch W, et al. Good practices for real-world data studies of treatment and\/or comparative effectiveness: recommendations from the Joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making. Value Health J Int Soc Pharmacoecon Outcomes Res. 2017;20:1003\u20138.","journal-title":"Value Health J Int Soc Pharmacoecon Outcomes Res"},{"key":"3186_CR107","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jval.2023.01.007","volume":"26","author":"LA Murphy","year":"2023","unstructured":"Murphy LA, Akehurst R, Sol\u00e0-Morales O, Cunningham D, Mestre-Ferrandiz J, Franklin M, et al. Structure and content of a taxonomy to support the use of real-world evidence by health technology assessment practitioners and healthcare decision Makers. Value Health J Int Soc Pharmacoecon Outcomes Res. 2023;26:20\u201331.","journal-title":"Value Health J Int Soc Pharmacoecon Outcomes Res"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03186-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03186-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03186-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T09:03:10Z","timestamp":1747472590000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03186-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":107,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["3186"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03186-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"4 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Carla Rognoni and Rosanna Tarricone (CERGAS, SDA Bocconi School of Management) have nothing to disclose. Robert Pohlmeier is an employee of Fresenius Medical Care Deutschland GmbH.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}